Biotech's 10 Biggest PR Disasters of 2012
By GMWatch,
GMWatch
| 12. 31. 2012
The 10 biggest GMO PR disasters of 2012
[For links, please refer to the original article here]
2012 was the year the lights came up on the biotech industry. Its claims, its tactics and its products all came under scrutiny and some of its biggest PR fairytales bit the dust. Here are some prime examples.
1. Fleeing Europe: The biotech bubble needs to appear to be constantly expanding but in early 2012 came the news that the GM and chemicals giant BASF was pulling its GM division out of Europe because it was facing opposition "from the majority of consumers, farmers and politicians." BASF also announced it was stopping the commercialization of its GM Amflora potato, one of only two GM crops authorized for cultivation in the European Union. The crop had been a commercial flop. The industry's only other crop grown in Europe, Monsanto's Mon810 GM maize, continued to face bans in a number of countries including France and Germany. Even GM crop trials are in decline and with BASF quitting Europe they're expected to decline still further...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
